Early data from a clinical trial of the dual CCR2/CCR5 inhibitor cenicriviroc in patients with NASH indeed indicated an effective antifibrotic activity [39,40]. This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.